We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

168 hedge funds and large institutions have $987M invested in Karyopharm Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 21

40% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $7.99M

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

7% more funds holding

Funds holding: 157 → 168 (+11)

4% more capital invested

Capital invested by funds: $949M → $987M (+$38.7M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.13% less ownership

Funds ownership: 5.91% → 5.78% (-0.13%)

Holders
168
Holders Change
+11
Holders Change %
+7.01%
% of All Funds
2.97%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
32
Increased
61
Reduced
44
Closed
21
Calls
$11.2M
Puts
$7.99M
Net Calls
+$3.23M
Net Calls Change
+$273K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$36M
2
LCM
Laurion Capital Management
New York
+$12.8M
3
CWG
C WorldWide Group
Denmark
+$9.27M
4
State Street
State Street
Massachusetts
+$8.51M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$7.75M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$87.6M
2
Two Sigma Investments
Two Sigma Investments
New York
-$19.3M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$15.5M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$11.6M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$10.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vontobel Holding
101
Vontobel Holding
Switzerland
$363K +$363K +1,565 New
Osaic Holdings
102
Osaic Holdings
Arizona
$359K -$1.39K -6 -0.4%
DADC
103
D.A. Davidson & Co
Montana
$356K +$355K +1,533 New
EGM
104
Engineers Gate Manager
New York
$349K -$233K -1,007 -40%
MFIM
105
Mesirow Financial Investment Management
Illinois
$345K +$345K +1,487 New
GCP
106
GSA Capital Partners
United Kingdom
$339K +$338K +1,460 New
MLICM
107
Metropolitan Life Insurance Company (MetLife)
New York
$337K – – –
HSBC Holdings
108
HSBC Holdings
United Kingdom
$330K +$35.9K +155 +12%
BCV
109
Banque Cantonale Vaudoise
Switzerland
$310K – – –
VWM
110
Vigilare Wealth Management
Arizona
$297K +$89.4K +386 +43%
Legal & General Group
111
Legal & General Group
United Kingdom
$294K -$1.85K -8 -0.6%
PCM
112
Prelude Capital Management
New York
$285K – – –
JMPWA
113
JP Morgan Private Wealth Advisors
California
$279K -$59.8K -258 -18%
Citigroup
114
Citigroup
New York
$272K +$20.2K +87 +8%
FMT
115
First Mercantile Trust
Tennessee
$267K +$41.2K +178 +18%
IA
116
Insight Advisors
Pennsylvania
$267K +$266K +1,148 New
PNC Financial Services Group
117
PNC Financial Services Group
Pennsylvania
$263K +$204K +881 +348%
AA
118
AlphaCentric Advisors
Puerto Rico
$263K +$263K +1,133 New
ACM
119
AlphaCrest Capital Management
New York
$262K -$51K -220 -16%
HF
120
HRT Financial
New York
$247K +$247K +1,066 New
Baird Financial Group
121
Baird Financial Group
Wisconsin
$239K +$21.1K +91 +10%
BRWA
122
B. Riley Wealth Advisors
Florida
$233K -$7.65K -33 -3%
BC
123
Bridgefront Capital
Texas
$232K +$232K +1,000 New
ASRS
124
Arizona State Retirement System
Arizona
$231K -$8.34K -36 -3%
MC
125
Moors & Cabot
Massachusetts
$226K +$228K +983 New
3 4
5
6 7

KPTI Hedge Fund Activity: Q4 2020 in Review

168 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2020, worth a combined $987M — up 4.1% from $949M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new KPTI positions and 21 closed out — a net gain of 11 holders — while 61 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $36M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $87.6M sold.

  • 168 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2020, up from 157 in Q3 2020.
  • Funds reported $987M of Karyopharm Therapeutics stock for Q4 2020, up 4.1% quarter-over-quarter.
  • 32 funds opened new Karyopharm Therapeutics positions in Q4 2020 and 21 closed out, a net change of +11 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2020 was Millennium Management, an estimated $36M added.
  • The largest Karyopharm Therapeutics seller in Q4 2020 was Avoro Capital Advisors, an estimated $87.6M sold.

Based on aggregated 13F filings for Q4 2020.